Our Research

In this section you will find current statistics on our products. Our drug for the treatment of brain and liver cancer has received (*) Orphan Drug Designation from the EMA.

SI-053

(brain tumor)

Discovery and Development
Preclinical Research
Clinical Research
Review
Post-Market Safety Monitor

SA-033

(liver tumor)

Discovery and Development
Preclinical Research
Clinical Research
Review
Post-Market Safety Monitor

SA-083

(lung tumor)

Discovery and Development
Preclinical Research
Clinical Research
Review
Post-Market Safety Monitor

In 2022, 320,000 adults were diagnosed with brain and CNS tumors, and 250,000 died (Global Cancer Observatory).

Surgery is critical for eliminating the bulk of the tumor, offering the best chance to prolong survival and alleviate symptoms.

However, malignant brain tumors like glioblastoma infiltrate surrounding healthy tissue. Glioblastoma is characterized by its highly aggressive nature and fast growth. This makes it very hard to treat, leading to recurrence and death.

The Stupp protocol, the standard of care for glioblastoma, includes maximum safe resection, radiotherapy (RT) and systemic temozolomide (TMZ).  This protocol extends survival by 10 months on average.

However, oral temozolomide causes systemic toxicity and poor drug delivery to brain cancer due to the blood-brain barrier. Many patients can’t complete chemotherapy due to side effects and disease progression, leaving high levels of residual microscopic disease and a high risk of recurrence.

Our analysis of 25 years of clinical studies involving 8713 patients with newly diagnosed glioblastoma revealed that adding systemic experimental treatment to the Stupp protocol only provided an additional 2.7 months of survival. Locally delivered experimental treatment resulted in an additional 2.9 months of survival. In contrast, Temodex, a prototype product of SI-053, extended survival by 5 months in addition to standard care, showing a 60% improvement in survival compared to the control group.

SI-053 allows direct delivery of temozolomide to the tumor, potentially prolonging survival, progression-free survival, and treatment-free intervals. To read more about SI-053/Temodex, please go to Our Products page.

SI-053 allows direct delivery of temozolomide to the tumor, potentially prolonging survival, progression-free survival, and treatment-free intervals.
To read more about SI-053/Temodex,
please go to Our Products page.